Publikationen (159) Publikationen von Luis María Máiz Carro

filter_list

2026

  1. Biochemical characteristics of inhaled antibiotics related to tolerability

    Farmacia Hospitalaria, Vol. 50, Núm. 2, pp. 87-96

  2. Improving the multidimensional scoring systems in bronchiectasis: the role of cellular biomarkers

    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, Vol. 30, Núm. 1, pp. 40-42

2025

  1. Aspergillus Pneumonia in an Immunocompetent Patient

    Open Respiratory Archives, Vol. 7, Núm. 2

  2. Bronchopulmonary colonization patterns in Spanish people with cystic fibrosis: Results of a national multicentre study

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 43, Núm. 6, pp. 309-316

  3. Current Evidence on the Usefulness of Potential Therapies in the Prevention of COPD Exacerbations: Beyond the Use of Bronchodilator Therapy and Inhaled Corticosteroids

    Open Respiratory Archives, Vol. 7, Núm. 2

  4. Effect of N-Acetylcysteine on Bronchiectasis in a Real-life Study. Data From the Spanish RIBRON Registry

    Archivos de Bronconeumologia, Vol. 61, Núm. 4, pp. 196-202

  5. Exploring the complexities of intestinal and pulmonary microbiota in cystic fibrosis: A multi-omics approach

    Respiratory Medicine, Vol. 248

  6. Persistent Blood Eosinophilia and Eosinopenia: Relationship with Outcomes in Bronchiectasis

    Archivos de Bronconeumologia, Vol. 61, Núm. 8, pp. 484-489

  7. Short-term Tolerance to Inhaled Antibiotics in Patients With Bronchial Infection not Associated With Cystic Fibrosis

    Open Respiratory Archives, Vol. 7, Núm. 3

  8. The impact of interstitial lung disease in patients with acid sphingomyelinase deficiency (ASMD) - A case series

    Respiratory Medicine Case Reports, Vol. 55

  9. Use of inhaled corticosteroids in bronchiectasis: Data from the European Bronchiectasis Registry (EMBARC)

    Thorax, Vol. 80, Núm. 6, pp. 358-368

  10. What is the optimal dose of N-acetylcysteine in adult patients with bronchiectasis?—data from the RIBRON registry

    Journal of Thoracic Disease, Vol. 17, Núm. 10, pp. 9003-9012

2024

  1. Aerosolized Ampicillin in a Patient With Recurrent Respiratory Infections

    Archivos de Bronconeumologia, Vol. 60, Núm. 9, pp. 604-605

  2. Airway clearance management in people with bronchiectasis: data from the European Bronchiectasis Registry (EMBARC)

    The European respiratory journal, Vol. 63, Núm. 6

  3. Bronchiectasis and asthma: Data from the European Bronchiectasis Registry (EMBARC)

    Journal of Allergy and Clinical Immunology, Vol. 153, Núm. 6, pp. 1553-1562

  4. Evaluation of Insulin Secretion and Continuous Glucose Monitoring in Patients with Cystic Fibrosis After Initiation of Transmembrane Conductance Regulator Modulator: A 52-Week Prospective Study

    Diabetology, Vol. 5, Núm. 6, pp. 554-565

  5. From ivacaftor to gene therapy, what has changed in cystic fibrosis?

    Revista de Patologia Respiratoria, Vol. 27, Núm. 4, pp. 138-148

  6. Genomic characterization of MRSA recovered from people with cystic fibrosis during two Spanish multicentre studies (2013 and 2021)

    JAC-Antimicrobial Resistance, Vol. 6, Núm. 5

  7. Objective sputum colour assessment and clinical outcomes in bronchiectasis: data from the European Bronchiectasis Registry (EMBARC)

    The European respiratory journal, Vol. 63, Núm. 4

  8. Reliability of blood eosinophil count in steady-state bronchiectasis

    Pulmonology